Won Ki Kang - Search Results

Year	Number of Results
2002	7
2003	8
2004	13
2005	16
2006	11
2007	20
2008	12
2009	21
2010	26
2011	24
2012	19
2013	14
2014	15
2015	28
2016	17
2017	25
2018	22
2019	28
2020	23
2021	18
2022	12
2023	9
2024	2

1

Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.

Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F. Raimondi A, et al. Among authors: kang wk. Eur J Cancer. 2024 May;203:114043. doi: 10.1016/j.ejca.2024.114043. Epub 2024 Apr 4. Eur J Cancer. 2024. PMID: 38598921

2

Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.

An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, Bi L, Lee H, Kim TJ, Lee SY, Moon J, Park RJ, Strickland MR, Park WY, Kang WK, Kim KM, Kim ST, Klempner SJ, Lee J. An M, et al. Among authors: kang wk. Cancer Discov. 2024 May 1;14(5):766-785. doi: 10.1158/2159-8290.CD-23-0857. Cancer Discov. 2024. PMID: 38319303 Free PMC article. Clinical Trial.

3

Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression.

Choi DH, Lee J, Lim HY, Kang WK, Jang JY, Jeon Y, Jeong SY, Jung YJ, Kim ST. Choi DH, et al. Among authors: kang wk. J Gastrointest Oncol. 2023 Dec 31;14(6):2324-2333. doi: 10.21037/jgo-23-418. Epub 2023 Dec 13. J Gastrointest Oncol. 2023. PMID: 38196548 Free PMC article.

4

The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.

Jeon Y, Lim SH, Lee J, Kang WK, Jang JY, Jeong SY, Choi D, Kim ST. Jeon Y, et al. Among authors: kang wk. J Gastrointest Oncol. 2023 Dec 31;14(6):2346-2353. doi: 10.21037/jgo-23-598. Epub 2023 Dec 27. J Gastrointest Oncol. 2023. PMID: 38196521 Free PMC article.

5

The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy.

Shin MK, Choi MG, Kim ST, Kang WK, Sohn TS, An JY, Lee JH, Lee JY. Shin MK, et al. Among authors: kang wk. Biomedicines. 2023 Nov 20;11(11):3097. doi: 10.3390/biomedicines11113097. Biomedicines. 2023. PMID: 38002099 Free PMC article.

6

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.

Hyung S, Ko J, Heo YJ, Blum SM, Kim ST, Park SH, Park JO, Kang WK, Lim HY, Klempner SJ, Lee J. Hyung S, et al. Among authors: kang wk. Sci Adv. 2023 Nov 24;9(47):eadk1098. doi: 10.1126/sciadv.adk1098. Epub 2023 Nov 24. Sci Adv. 2023. PMID: 38000030 Free PMC article.

7

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.

Lim SH, Cho HJ, Kim KM, Lim HY, Kang WK, Lee J, Park YS, Kim HC, Kim ST. Lim SH, et al. Among authors: kang wk. Oncol Res. 2023 Sep 15;31(6):855-866. doi: 10.32604/or.2023.030374. eCollection 2023. Oncol Res. 2023. PMID: 37744267 Free PMC article.

8

Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.

Shin M, Ahn S, Jung J, Hyung S, Kim KM, Kim ST, Kang WK, Lee J. Shin M, et al. Among authors: kang wk. Cancer Med. 2023 Sep;12(18):18633-18642. doi: 10.1002/cam4.6472. Epub 2023 Sep 1. Cancer Med. 2023. PMID: 37654198 Free PMC article.

9

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer.

Jang JY, Jeon Y, Jeong SY, Lim SH, Kang WK, Lee J, Kim ST. Jang JY, et al. Among authors: kang wk. J Gastric Cancer. 2023 Jul;23(3):476-486. doi: 10.5230/jgc.2023.23.e29. J Gastric Cancer. 2023. PMID: 37553133 Free PMC article.

10

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).

Ryu MH, Lee KH, Shen L, Yeh KH, Yoo C, Hong YS, Park YI, Yang SH, Shin DB, Zang DY, Kang WK, Chung IJ, Kim YH, Ryoo BY, Nam BH, Park YS, Kang YK. Ryu MH, et al. Among authors: kang wk. Cancer Med. 2023 Apr;12(7):7784-7794. doi: 10.1002/cam4.5536. Epub 2022 Dec 14. Cancer Med. 2023. PMID: 36515003 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

328 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Results by year